FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310136401> ?p ?o ?g. }

• W4310136401 endingPage "761.e7" @default.
• W4310136401 startingPage "751" @default.
• W4310136401 abstract "Human cathelicidin LL-37 is a multifunctional antimicrobial peptide that exhibits antimicrobial and immunomodulatory activities. LL-37 regulates skin barrier function and was recently reported to activate autophagy in macrophages. Because autophagy deficiency is associated with skin diseases characterized by a dysfunctional epidermal barrier, we hypothesized that LL-37 might regulate the skin barrier through autophagy modulation. We showed that LL-37 activated autophagy in human keratinocytes and three-dimensional skin equivalent models as indicated by increases in LC3 puncta formation, decreases in p62, and autophagosome and autolysosome formation. LL-37‒induced autophagy was suppressed by P2X7 receptor, adenosine monophosphate‒activated protein kinase, and unc-51-like kinase 1 inhibitors, suggesting that the P2X7, adenosine monophosphate‒activated protein kinase, and unc-51-like kinase 1 pathways are involved. Moreover, LL-37 enhanced the phosphorylation of adenosine monophosphate‒activated protein kinase and unc-51-like kinase 1. In addition, LL-37‒mediated autophagy involves the mechanistic target of rapamycin and MAPK pathways. Interestingly, the LL-37‒induced distribution of tight junction proteins and improvement in the tight junction barrier were inhibited in autophagy-deficient keratinocytes and keratinocytes and skin models treated with autophagy inhibitors, indicating that the LL-37‒mediated tight junction barrier is associated with autophagy activation. Collectively, these findings suggest that LL-37 is a potential therapeutic target for skin diseases characterized by dysfunctional autophagy and skin barriers. Human cathelicidin LL-37 is a multifunctional antimicrobial peptide that exhibits antimicrobial and immunomodulatory activities. LL-37 regulates skin barrier function and was recently reported to activate autophagy in macrophages. Because autophagy deficiency is associated with skin diseases characterized by a dysfunctional epidermal barrier, we hypothesized that LL-37 might regulate the skin barrier through autophagy modulation. We showed that LL-37 activated autophagy in human keratinocytes and three-dimensional skin equivalent models as indicated by increases in LC3 puncta formation, decreases in p62, and autophagosome and autolysosome formation. LL-37‒induced autophagy was suppressed by P2X7 receptor, adenosine monophosphate‒activated protein kinase, and unc-51-like kinase 1 inhibitors, suggesting that the P2X7, adenosine monophosphate‒activated protein kinase, and unc-51-like kinase 1 pathways are involved. Moreover, LL-37 enhanced the phosphorylation of adenosine monophosphate‒activated protein kinase and unc-51-like kinase 1. In addition, LL-37‒mediated autophagy involves the mechanistic target of rapamycin and MAPK pathways. Interestingly, the LL-37‒induced distribution of tight junction proteins and improvement in the tight junction barrier were inhibited in autophagy-deficient keratinocytes and keratinocytes and skin models treated with autophagy inhibitors, indicating that the LL-37‒mediated tight junction barrier is associated with autophagy activation. Collectively, these findings suggest that LL-37 is a potential therapeutic target for skin diseases characterized by dysfunctional autophagy and skin barriers." @default.
• W4310136401 created "2022-11-30" @default.
• W4310136401 creator A5000822704 @default.
• W4310136401 creator A5002129976 @default.
• W4310136401 creator A5006914306 @default.
• W4310136401 creator A5016241753 @default.
• W4310136401 creator A5031964705 @default.
• W4310136401 creator A5040549451 @default.
• W4310136401 creator A5050395616 @default.
• W4310136401 creator A5052820334 @default.
• W4310136401 creator A5053944706 @default.
• W4310136401 creator A5059708724 @default.
• W4310136401 creator A5065203157 @default.
• W4310136401 creator A5066022063 @default.
• W4310136401 creator A5067951016 @default.
• W4310136401 creator A5088986458 @default.
• W4310136401 date "2023-05-01" @default.
• W4310136401 modified "2023-10-12" @default.
• W4310136401 title "Cathelicidin LL-37 Activates Human Keratinocyte Autophagy through the P2X₇, Mechanistic Target of Rapamycin, and MAPK Pathways" @default.
• W4310136401 cites W1520340830 @default.
• W4310136401 cites W1594293927 @default.
• W4310136401 cites W1896221069 @default.
• W4310136401 cites W1964454463 @default.
• W4310136401 cites W1970637701 @default.
• W4310136401 cites W1971896370 @default.
• W4310136401 cites W1977767269 @default.
• W4310136401 cites W1978419646 @default.
• W4310136401 cites W1995439337 @default.
• W4310136401 cites W1999661190 @default.
• W4310136401 cites W2001045944 @default.
• W4310136401 cites W2005002911 @default.
• W4310136401 cites W2005427598 @default.
• W4310136401 cites W2009852312 @default.
• W4310136401 cites W2016467209 @default.
• W4310136401 cites W2025955747 @default.
• W4310136401 cites W2058160101 @default.
• W4310136401 cites W2068650355 @default.
• W4310136401 cites W2069492069 @default.
• W4310136401 cites W2074648420 @default.
• W4310136401 cites W2083702857 @default.
• W4310136401 cites W2089440239 @default.
• W4310136401 cites W2094036101 @default.
• W4310136401 cites W2104558541 @default.
• W4310136401 cites W2108086395 @default.
• W4310136401 cites W2110806257 @default.
• W4310136401 cites W2112649783 @default.
• W4310136401 cites W2116367518 @default.
• W4310136401 cites W2116901311 @default.
• W4310136401 cites W2128537698 @default.
• W4310136401 cites W2132024007 @default.
• W4310136401 cites W2135894423 @default.
• W4310136401 cites W2305435220 @default.
• W4310136401 cites W2323438857 @default.
• W4310136401 cites W2397416311 @default.
• W4310136401 cites W2409281298 @default.
• W4310136401 cites W2511312146 @default.
• W4310136401 cites W2588013596 @default.
• W4310136401 cites W2746907113 @default.
• W4310136401 cites W2748137738 @default.
• W4310136401 cites W2792139654 @default.
• W4310136401 cites W2795363192 @default.
• W4310136401 cites W2945161427 @default.
• W4310136401 cites W2949728293 @default.
• W4310136401 cites W2970684247 @default.
• W4310136401 cites W2990912547 @default.
• W4310136401 cites W3005189635 @default.
• W4310136401 cites W3044049851 @default.
• W4310136401 cites W3045989319 @default.
• W4310136401 cites W3108936441 @default.
• W4310136401 cites W3133615374 @default.
• W4310136401 cites W3153998827 @default.
• W4310136401 cites W3166472766 @default.
• W4310136401 cites W4285389910 @default.
• W4310136401 doi "https://doi.org/10.1016/j.jid.2022.10.020" @default.
• W4310136401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36455652" @default.
• W4310136401 hasPublicationYear "2023" @default.
• W4310136401 type Work @default.
• W4310136401 citedByCount "1" @default.
• W4310136401 countsByYear W43101364012023 @default.
• W4310136401 crossrefType "journal-article" @default.
• W4310136401 hasAuthorship W4310136401A5000822704 @default.
• W4310136401 hasAuthorship W4310136401A5002129976 @default.
• W4310136401 hasAuthorship W4310136401A5006914306 @default.
• W4310136401 hasAuthorship W4310136401A5016241753 @default.
• W4310136401 hasAuthorship W4310136401A5031964705 @default.
• W4310136401 hasAuthorship W4310136401A5040549451 @default.
• W4310136401 hasAuthorship W4310136401A5050395616 @default.
• W4310136401 hasAuthorship W4310136401A5052820334 @default.
• W4310136401 hasAuthorship W4310136401A5053944706 @default.
• W4310136401 hasAuthorship W4310136401A5059708724 @default.
• W4310136401 hasAuthorship W4310136401A5065203157 @default.
• W4310136401 hasAuthorship W4310136401A5066022063 @default.
• W4310136401 hasAuthorship W4310136401A5067951016 @default.
• W4310136401 hasAuthorship W4310136401A5088986458 @default.
• W4310136401 hasConcept C170493617 @default.
• W4310136401 hasConcept C184235292 @default.
• W4310136401 hasConcept C185592680 @default.
• W4310136401 hasConcept C190283241 @default.

• next